Mobocertinib added in NICE guidelines
NICE guidelines have added the guidance on mobocertinib to the systemic anti-cancer therapy treatment pathways for advanced non-small-cell lung cancer.
They would like your feedback on how the treatment pathways present content from different sources (NICE technology appraisal guidance, guideline recommendations, and expert input). To comment, go to the link below on systemic anti-cancer therapy for advanced non-small-cell lung cancer and fill in the pop-up survey.
Recent Posts
Impact of Practice-Level Telehealth on Quality Outcomes in Chronic Care
Practice-level telehealth quality outcomes remained stable for access and preventable hospitalizations among Medicare beneficiaries with chronic conditions during the COVID-19 pandemic. High-adopting primary care practices preserved care continuity while delivering modestly lower performance on s...
African Pharmacogenomic Integration Enhancing Essential Medicine Prescribing in Africa
African Pharmacogenomic Integration has become an urgent policy priority, with evidence showing that more than 10 percent of essential medicines across Africa require genetically guided prescribing to prevent harm and improve outcomes in diverse populations. Current dosage guidelines for HIV, ...
Pharmaceutical Manufacturing Affordability as a Key to South Africa’s Local Production Goals
Pharmaceutical manufacturing affordability remains the decisive factor in South Africa’s efforts to build domestic capacity for essential medicines and vaccines. Government, industry and research leaders who met at the TIPS Development Dialogue on 17 June made clear that economic barriers to acce...